Trial Profile
An open-label multicenter study to assess the safety of AVP-923 [dextromethorphan/quinidine; Neurodex (TM)] in the treatment of patients with pseudobulbar affect
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Jul 2016
Price :
$35
*
At a glance
- Drugs Dextromethorphan/quinidine (Primary)
- Indications Emotional lability
- Focus Adverse reactions
- Sponsors Avanir Pharmaceuticals
- 08 Oct 2005 New trial record.